Free Trial

Turnstone Biologics Q4 2024 Earnings Report

Turnstone Biologics logo
$0.38 0.00 (-1.21%)
As of 11:44 AM Eastern

Turnstone Biologics EPS Results

Actual EPS
-$0.56
Consensus EPS
-$0.69
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Turnstone Biologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Turnstone Biologics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Turnstone Biologics Earnings Headlines

Turnstone Biologics reports Q4 EPS (56c) vs (73c) last year
Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
See More Turnstone Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Turnstone Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Turnstone Biologics and other key companies, straight to your email.

About Turnstone Biologics

Turnstone Biologics (NASDAQ:TSBX), a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

View Turnstone Biologics Profile

More Earnings Resources from MarketBeat